Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 14 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11826408

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  2. US 11819512

    Solid forms of a CD73 inhibitor and the use thereof

    Arcus Biosciences, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  3. US 11820982

    Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  4. US 11820775

    Pyrrolopyrimidine ITK inhibitors

    Aclaris Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  5. US 11813257

    Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

    Disc Medicine, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  6. US 11813267

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  7. US 11814377

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  8. US 11807649

    Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

    EnLiven Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  9. US 11807658

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  10. US 11807646

    4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)

    ALMAC DISCOVERY LIMITED · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  11. US 11807605

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  12. US 11802110

    2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase

    Oxford Drug Design Limited · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted
  13. US 11795180

    Formulation of a pan-JAK inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  14. US 11793855

    TFPI inhibitors and methods of use

    Takeda Pharmaceutical Company Limited · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  15. US 11787796

    Plasma Kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  16. US 11786500

    Glutaminase inhibitor therapy

    The Board of Regents of the University of Texas System · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  17. US 11786517

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  18. US 11786541

    Inhibitor of sphingosine kinase 2 for treating Ebola

    RedHill Biopharma Ltd. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  19. US 11787762

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

    Arcus Biosciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  20. US 11780837

    CXCR4 inhibitors and uses thereof

    X4 Pharmaceuticals, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  21. US 11780821

    Inhibitors of fibroblast activation protein

    PRAXIS BIOTECH LLC · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  22. US 11780845

    FGFR inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  23. US 11773393

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  24. US 11767526

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted